Tag: Cybin Corp - Page 2 - Psychedelic Alpha

Access exclusive insights, data and interviews with Pα+: learn more and subscribe today.

Read more about the article Cybin Awarded Notice of Allowance from U.S. Patent and Trademark Office for CYB004 (Deuterated Psychedelic Tryptamine) for the Treatment of Anxiety Disorders

Cybin Awarded Notice of Allowance from U.S. Patent and Trademark Office for CYB004 (Deuterated Psychedelic Tryptamine) for the Treatment of Anxiety Disorders

Post published:December 15, 2021
Post category:Press Release

Read more about the article Cybin Confirms Scientific Advice Meeting with UK Medical and Healthcare Products Regulatory Agency for Lead Candidate CYB003 for the Treatment of Major Depressive Disorder and Alcohol Use Disorder

Cybin Confirms Scientific Advice Meeting with UK Medical and Healthcare Products Regulatory Agency for Lead Candidate CYB003 for the Treatment of Major Depressive Disorder and Alcohol Use Disorder

Post published:December 8, 2021
Post category:Press Release

Read more about the article Cybin Announces FDA Investigational New Drug and Institutional Review Board Approvals for a Co-Funded Phase 2 Clinical Trial to Treat Frontline Clinicians Experiencing COVID-Related Distress

Cybin Announces FDA Investigational New Drug and Institutional Review Board Approvals for a Co-Funded Phase 2 Clinical Trial to Treat Frontline Clinicians Experiencing COVID-Related Distress

Post published:November 30, 2021
Post category:Press Release

Read more about the article Cybin Awards Grant for Psychedelic Treatment Clinic at Lenox Hill Hospital to Benefit Underserved Communities

Cybin Awards Grant for Psychedelic Treatment Clinic at Lenox Hill Hospital to Benefit Underserved Communities

Post published:November 23, 2021
Post category:Press Release

Read more about the article Cybin Announces Positive CYB003 Data Demonstrating Significant Advantages Over Oral Psilocybin for Treatment of Mental Health

Cybin Announces Positive CYB003 Data Demonstrating Significant Advantages Over Oral Psilocybin for Treatment of Mental Health

Post published:November 8, 2021
Post category:Press Release

Read more about the article Cybin Granted DEA Schedule I Manufacturing License

Cybin Granted DEA Schedule I Manufacturing License

Post published:November 4, 2021
Post category:Press Release

Read more about the article Cybin Hosting Research and Development Briefing on November 8, 2021

Cybin Hosting Research and Development Briefing on November 8, 2021

Post published:November 2, 2021
Post category:Press Release

Read more about the article Cybin Announces Launch of EMBARK Psychedelic Facilitator Training Program

Cybin Announces Launch of EMBARK Psychedelic Facilitator Training Program

Post published:October 28, 2021
Post category:Press Release

Read more about the article Cybin Announces FDA Investigational New Drug Authorization of Cybin’s Sponsored Feasibility Study Using Kernel Flow Technology

Cybin Announces FDA Investigational New Drug Authorization of Cybin’s Sponsored Feasibility Study Using Kernel Flow Technology

Post published:October 26, 2021
Post category:Press Release

Read more about the article Cybin Announces Completion of 74 Pre-Clinical Psychedelic Molecule Studies

Cybin Announces Completion of 74 Pre-Clinical Psychedelic Molecule Studies

Post published:October 19, 2021
Post category:Press Release

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.